golden empire jili tricks
During the construction of Hobart’s Veterans Elementary Hobart High teacher Greg Crouch stood outside piloting a drone as it hovered above the scene. “I wanted to get a wide shot,” Crouch said as he directed his drone over residences to achieve his filmmaking goal of documenting the school’s construction. A curious neighbor saw the drone and called the police. Crouch showed police his commercial drone pilot’s license, explained his mission, and police departed. Drone sightings are increasing across the country and stirring up mysteries and intrigue even as the alien-like devices are wending their way into our lives from filming NFL games to fertilizing farm fields. In recent weeks, omnipresent groupings of drones disturbed residents in New Jersey, Pennsylvania and New York. Their concerns stirred up lawmakers who are asking the federal government for answers. In this image taken from video provided by MartyA45_, several drones appear to be flying over Randolph, N.J., on Wednesday, Dec. 4, 2024. (MartyA45_ /TMX via AP, File) The federal Department of Homeland Security is investigating the sightings, but so far nothing nefarious has been reported. Even as drones become more common, they still conjure up paranoia and confusion among Americans unfamiliar with drone regulations. Educators though have embraced the new technology. Districts like Hobart and Valparaiso have incorporated drones into the curriculum. Students in Crouch’s Hobart High advanced broadcasting class use the school’s drone to practice filmmaking techniques such as aerial photography at football practices to aid coaches. Hobart’s school board recently accepted funding for the purchase of a new drone. Crouch sees many benefits of the drone camera’s capabilities. “You can do an area of a field to assess how much water was collected during a flood and it can fly back home,” he said. “We can really start utilizing this in a cross-platform with Project Lead the Way’s Cart Club, too.” In that course, students build their own manned go-carts from scratch and race them. The drone adds aerial photography and data on turns and maneuvers. In 2021, Valparaiso High received a $400,000 city redevelopment Challenge Grant to establish an aviation flight course that includes drone piloting, a skill becoming more popular with the U.S. military. In Hobart, police who work as school resource officers asked for aerial photography footage of high school parking lots to instruct parents where to park and line up for pickup during dismissal. “They use it to better route traffic,” Crouch said. Besides piloting skills, Crouch teaches students Indiana’s drone rules of the air. “We touch upon how to fly, when, and what you are allowed to fly over,” Crouch said. “The biggest rule is don’t impede manned vehicles.” Crouch said there are two types of drone pilot licenses – hobbyist and commercial. Nearly 800,000 are already registered for recreational and commercial use. Many drones, however, aren’t registered, officials said. Americans alarmed at the appearance of a drone can’t just fire a shot at it without consequences. It’s a federal crime to shoot at an aircraft. Also: · Indiana-specific laws call for police to obtain a search warrant before conducting drone surveillance over private property without owner consent. · Sex offenders can’t capture images or track people with a drone. · The state Department of Natural Resources restricts drone flying at their park sites to certain properties and permission is required. · Drones can’t be flown to harass neighbors or take unauthorized videos or photos above private property. · Hunters can’t use drones to scout, search or detect wild animals. A hunter who legally hunted an animal can use a drone with an infrared camera to retrieve the animal’s body. The FAA requires recreational drone pilots to: · Keep the drone in sight at all times. · Don’t interfere with other aircraft. · Fly at or below 400 feet. Drones may be popular gifts for hobbyists, but officials say new pilots should learn the rules before they fly them. For information, visit: faa.gov/uas/recreational_flyers . Carole Carlson is a freelance reporter for the Post-Tribune.
Now that the election is behind us, market watchers are digging into what Trump’s victory could mean for the economy in the coming months. As the former and future President prepares to take office, certain economic trends have already become clear: inflation has been slowing throughout much of this year, and the Federal Reserve has adopted a lower-rate policy – both of which are likely to support economic growth. Don't Miss our Black Friday Offers: Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter More importantly, Trump has signaled his intent to pursue a deregulatory economic policy, consistent with his previous administration. Historically, such periods of deregulation have often fueled economic growth, setting the stage for a potential phase of expansion. This is the thesis behind recent comments from Raymond James’ market strategist Matt Orton, who stated, “We are heading into a very favorable seasonal period for the overall economy. So, I am very optimistic about where the markets go. I am more optimistic about the prospects that the growth we have been seeing can be maintained.” Against this backdrop, Raymond James analysts have spotlighted two stocks with big upside — including one with a potential gain of nearly 440%. What’s more, according to the TipRanks database , both stocks boast Strong Buy ratings from the analyst consensus. Let’s see why they are drawing plaudits across the board. Mural Oncology (MURA) Imagine a world where cancer treatments harness the body’s own defenses, using the immune system to fight back more effectively. That’s the vision behind Mural Oncology, a clinical-stage biopharmaceutical company focused on advancing cancer care. Mural has developed a proprietary protein engineering platform to create new cytokine-based oncological immunotherapies. At the forefront of Mural’s pipeline is nemvaleukin alfa, a novel engineered IL-2 variant. IL-2 is a cytokine that stimulates both effector immune cells and regulatory T (Treg) cells, making it a prime candidate for anti-tumor activity. The company plans to develop nemvaleukin into a best-in-class immunotherapy and currently has the drug undergoing multiple human clinical trials targeting conditions such as platinum-resistant ovarian cancer (PROC), mucosal melanoma, and cutaneous melanoma. Mural’s two leading clinical trials are ARTISTRY-7, a Phase 3 trial testing nemvaleukin against PROC, and ARTISTRY-6, a Phase 2 trial testing the drug in combination with pembrolizumab against unresectable or metastatic mucosal melanoma. The former has completed enrollment with 456 patients, and interim overall survival results are expected to be released early next year, either in late Q1 or early Q2. The ARTISTRY-6 trial has 92 patients enrolled, and Mural expects to release top-line results from cohort 2 during 2Q25. These pivotal trials build on the success of ARTISTRY-1, a Phase 1/2 open-label study that evaluated nemvaleukin’s safety, tolerability, and preliminary efficacy. Results showed that nemvaleukin was well-tolerated and demonstrated durable responses in both monotherapy and combination therapy. With several potential catalysts on the horizon and a share price of only $3.35, Raymond James analyst Laura Prendergast sees a compelling opportunity for investors. “We believe MURA is currently undervalued for the following reasons: 1) lead asset, nemvaluekin, has near-term commercial opportunity that doesn’t seem to be on the radar yet for many investors, 2) management and board have notable experience that inspire confidence in ability to maneuver late stage drug development/commercial launch/BD execution; 3) MURA is currently trading at a 65% discount to cash and at 98% discount to its small cap biotech peer group,” Prendergast explained. “If MURA can execute on [its] catalysts, we anticipate the company could become a major buyout target. We analyzed recent biotech acquisitions with similar 5-year forward sales estimates to MURA. Average historical take out multiple for this peer group is 5x EV/5-year forward sales which implies a potential deal value of ~$1.2B and $48 target price for MURA,” the analyst further noted. For now, Prendergast rates MURA shares a Strong Buy, while her $18 price target suggests a robust upside of ~440% on the one-year horizon. (To watch Prendergast’s track record, click here ) Other analysts are also optimistic about the cancer drug maker. MURA’s Strong Buy consensus rating breaks down into 3 Buys and no Holds or Sells. In addition, the $16.33 average price target puts the upside potential at 387%. (See MURA stock forecast ) Disc Medicine (IRON) The next pick from Raymond James is Disc Medicine, a clinical-stage biopharmaceutical company dedicated to advancing treatments for hematologic diseases. Focused on the heme and iron pathways critical to red blood cell biology, the company aims to address some of the most pressing challenges in blood-related disorders. Disc Medicine’s approach is driven by two key technology platforms. The heme synthesis modulation platform focuses on erythropoiesis, the process of red blood cell production. Meanwhile, the hepcidin pathway modulation platform addresses iron homeostasis, regulating how iron is absorbed, stored, and utilized – critical for hemoglobin production and healthy red blood cell development. The company’s leading drug candidate, bitopertin, is a GlyT1 inhibitor designed to modulate heme biosynthesis. Disc Medicine is developing bitopertin as a potential treatment for erythropoietic porphyrias (EPP), a rare group of genetic blood disorders that cause extreme sensitivity to sunlight, severe pain, and skin blistering. Currently, no cure exists for EPP. Disc Medicine recently concluded a successful end-of-Phase 2 meeting with the FDA and plans to provide updates in the first quarter of 2025. The company is also preparing to launch a follow-up clinical trial by mid-2025. In addition, Disc Medicine has seen success with its second drug candidate, DISC-0974. This is a new therapeutic agent under study as a treatment for various types of anemia, including anemia of myelofibrosis (MF) and anemia associated with chronic kidney disease (CKD). The drug candidate is a monoclonal antibody and a first-in-class antagonist of hemojuvelin, designed to enhance iron levels in patients with anemia. The company has an ongoing Phase 1b study on the CKD track, and has plans to initiate a Phase 2 study on the MF track before the end of this year. All of this has caught the eye of Raymond James analyst Danielle Brill who wrote: “Disc Medicine has achieved regulatory alignment to file for accelerated approval for their lead asset bitopertin in EPP, representing our prior bull case scenario. This permits earlier market access for the company in addition to removing the risk having to run a large Phase 3 trial using a difficult primary endpoint... We expect a filing next year, with approval/launch by ~1H26 (RJ estimate).” “Furthermore,” the analyst added, “we have increasing confidence in Disc’s next pipeline asset DISC-0974 for the treatment of MF and CKD anemia, for which we recently saw positive proof-of-concept efficacy in CKD anemia in a Ph 1 SAD study (prior note). We are optimistic ahead of full Ph 1b data in MF anemia which are to be presented at ASH, along with other incremental updates across Disc’s pipeline.” This stance backs up the analyst’s Strong Buy rating on IRON stock, a rating that she compliments with a $110 price target – pointing towards a ~70% upside potential for the coming year. (To watch Brill’s track record, click here ) Brill’s colleagues on Wall Street are also in agreement. There are 10 recent analyst reviews of this stock on record and they are unanimously positive, giving IRON shares their Strong Buy consensus rating. The stock is currently trading for $64.96 and has an average target price of $92.40, suggesting a one-year upside of 42%. (See IRON stock forecast ) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.Seahawks have taken a bumpy path to first place in the NFC West
Jimmy Carter: Many evolutions for a centenarian ‘citizen of the world’Disgraceful and cynical are some of the words Premier Chris Minns has used to describe a reported vote to refer him to the state's corruption watchdog. Login or signup to continue reading An inquiry into the pitch to sell the Australian Turf Club's Rosehill Racecourse in Sydney's west and turn it into tens of thousands of homes will deliver its report on Friday. But late on Wednesday the NSW premier responded to media reports the committee conducting the inquiry will call for him to be referred to the Independent Commission Against Corruption, describing them as allegations based on no fact or evidence. "It's disgraceful to politicise the ICAC with unsubstantiated rumours," Mr Minns said. "This is an old fashioned smear from a group of politicians opposed to changes at Rosehill," he added. The unsubstantiated allegations were a cynical attempt at political point scoring, Mr Minns said. Independent MP Mark Latham, a member of the committee, and of the turf club, claimed via social media on Thursday there is evidence to justify the ICAC referral, based on a meeting the premier had in October 2023. Mr Minns described the turf club's head of membership and corporate affairs Steve McMahon as a friend of more than 20 years in August, after Mr McMahon appeared at the committee inquiry earlier that month. The committee was told Mr McMahon pitched the idea to the turf club's chairman Peter McGauran on October 26, 2023. The premier had a "meet and greet" with the turf club four days later according to ministerial diaries. Mr McMahon told the inquiry the meeting was to discuss the idea and the process for pitching it to the government, before investing member resources in a proposal. "You want to make sure that (the government) are not going to be automatically opposed to such a thing," he said. Mr Minns told budget estimates in August the proposal was announced before turf club members voted on the sale in the interest of transparency. Australian Associated Press DAILY Today's top stories curated by our news team. Also includes evening update. WEEKDAYS Grab a quick bite of today's latest news from around the region and the nation. WEEKLY The latest news, results & expert analysis. WEEKDAYS Catch up on the news of the day and unwind with great reading for your evening. WEEKLY Get the editor's insights: what's happening & why it matters. WEEKLY Love footy? We've got all the action covered. WEEKLY Every Saturday and Tuesday, explore destinations deals, tips & travel writing to transport you around the globe. WEEKLY Get the latest property and development news here. WEEKLY Going out or staying in? Find out what's on. WEEKDAYS Sharp. Close to the ground. Digging deep. Your weekday morning newsletter on national affairs, politics and more. WEEKLY Follow the Newcastle Knights in the NRL? Don't miss your weekly Knights update. TWICE WEEKLY Your essential national news digest: all the big issues on Wednesday and great reading every Saturday. WEEKLY Get news, reviews and expert insights every Thursday from CarExpert, ACM's exclusive motoring partner. TWICE WEEKLY Get real, Australia! Let the ACM network's editors and journalists bring you news and views from all over. AS IT HAPPENS Be the first to know when news breaks. DAILY Your digital replica of Today's Paper. Ready to read from 5am! DAILY Test your skills with interactive crosswords, sudoku & trivia. Fresh daily!We’re just days away at this point from putting 2024 in our rearview mirror — which, for those of us who cover all things streaming, means that it’ll soon be time to turn our attention to what all the major streamers have teed up for the year to come. In this post, I’m going to take a closer look at three upcoming that will be available on in 2025. They don’t have official release dates yet, but what’s already certain is that all three of these will dominate the cultural conversation once they arrive. HBO has already teased a look at its jam-packed release slate for 2025, via a sizzle reel that offered sneak peeks of new seasons of and , in addition to shows like , , and . For the moment, there are the three upcoming HBO titles that I’m most excited for — arranged in no particular order, we’ll start things off with a return to Westeros. is getting another highly anticipated addition to the franchise in the coming year, via the spinoff . In terms of what we know about it so far: The story is set a century before the events of the OG series, in an age when the Targaryen line still controls the Iron Throne and “the memory of the last dragon has not yet passed from living memory.” At the story’s center are two unlikely heroes wandering Westeros — a naive but courageous young knight named Ser Duncan the Tall and his diminutive squire Egg. Creator George R.R. Martin has given interviews in the past in which he’s talked about wanting to tell more “small” stories like this one within the larger world of — in the style of , which took two minor characters from and focused on them rather than the bigger and more familiar story. This new spinoff, needless to say, promises an exciting return to the franchise’s world of politics and power struggles. Sign up for the most interesting tech & entertainment news out there. By signing up, I agree to the and have reviewed the for this next upcoming HBO series, which dropped back in September, has already whetted the appetites of fans craving the new season of . The relationship between Pedro Pascal’s Joel and Bella Ramsey’s Ellie will obviously continue to be core to the show. Season 2 will also bring us the continued presence of the fearsome Clickers, as well as the Seraphite religious sect. The story will pick up after the dramatic first season finale, which saw Joel and Ellie reach Salt Lake City and the latter being resolute in accepting that her immunity might be the only path toward a cure for the show’s pandemic. New characters who will join the show this season include Kaitlyn Dever’s Abby, as well as Ellie’s love interest Dina, played by Isabela Merced. The luxury hotel chain at the center of this next popular HBO series will expand its fictional footprint to Thailand for the third season of , following the brand welcoming guests to Hawaii and Sicily in Seasons 1 and 2. The great draw of the show from creator Mike White is how it uses a luxurious setting as the backdrop for slice-of-life stories about both guests and hotel staff, mixing dark humor and social satire to create one of the most memorable TV releases of the last several years. The cast for Season 3 will include Carrie Coon, Walton Goggins, Michelle Monaghan, and Parker Posey, with Blackpink member and Thailand native Lisa (credited as Lalisa Manobal) also making an appearance. Beyond that, we know almost nothing of the new season’s plot. Both previous seasons, of course, opened with a shot of an unidentified body, setting up a mystery that propelled each season’s story. Meanwhile, there’s already been talk of a potential fourth season in the works, even before HBO gives us a release date for Season 3.
Seahawks have taken a bumpy path to first place in the NFC West
I Loved Playing For Man Utd - But Fergusons Treatment Made Me Join Arch-Rivals
None
Republican Miller-Meeks wins reelection after recount in close Iowa congressional race
Kyle Richards does not approve of The Real Housewives of Beverly Hills costars Dorit Kemsley and Sutton Stracke ’s current feud. “I do not like when anybody talks about people’s looks or their financial situations. It’s ugly,” Richards, 55, said to Page Six on Saturday, November 24. “Listen, I’ve had my arguments. We disagree on the show, but I don’t do ugly.” She continued: “I don’t hit below the belt. I don’t like that.” The drama between Kemsley, 48, and Stracke, 53, began last month, when Stracke did a joint interview with Real Housewives of Salt Lake City star Lisa Barlow for MTV UK . The Housewives teamed up to play a game of Who Even Am I? where they had to guess the identity of the celebrity based on a series of clues. When the women got to Kemsley, the digs got personal. As Stracke held up a photo of her RHOBH costar, Barlow responded that she “holds grudges” and “lives way above her means.” Stracke ultimately guessed Kemsley and confessed that they still had unresolved issues to work through. “I don’t think she ever let the mouse go,” Stacke said to Barlow. “The lady can’t get a hint.” Barlow, for her part, paid Kemsley a compliment by calling her “pretty.” Stracke retorted, “Well, when you’ve had enough surgery anybody can be pretty.” After word got out of Stracke’s diss, Kemsley decided to fire back. “Why hasn’t Sutton done [plastic surgery] then?” she said during a November interview with Page Six . “She has the money, right? She can afford ... plastic surgery, so why hasn’t she done it if it is that easy? I’m just curious.” Kemsley also cleared the air regarding her costar’s plastic surgery claims, stating that she hasn’t had any work done aside from a breast augmentation. “I stand here today ... hand on my heart, promise you, I would happily, happily tell you if I did anything other than my boobs,” she confessed “And I have not.” While Stracke and Kemsley have their beef outside of RHOBH , the women have also been at odds with Richards this season. In the season 14 trailer , which gives fans a glimpse of the upcoming season, viewers saw the trio get into a heated argument after a dinner party. You have successfully subscribed. By signing up, I agree to the Terms and Privacy Policy and to receive emails from Us Weekly Check our latest news in Google News Check our latest news in Apple News “God gave you two ears and one mouth for a reason, can you let me talk?” Richards retorted, while Kemsley clapped back, “It’s OK Kyle, it’s time for you to f—ing listen.” After the trailer dropped, Stracke weighed in on the intense moment. “My thoughts were, ‘Let’s not have the police called on us,’” Stracke exclusively told Us Weekly at Hayu FanFest in London earlier this month.KBC Group NV raised its stake in shares of Cable One, Inc. ( NYSE:CABO – Free Report ) by 45.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 160 shares of the company’s stock after purchasing an additional 50 shares during the period. KBC Group NV’s holdings in Cable One were worth $56,000 as of its most recent filing with the Securities & Exchange Commission. Other hedge funds have also modified their holdings of the company. Jane Street Group LLC grew its stake in shares of Cable One by 880.9% during the first quarter. Jane Street Group LLC now owns 14,870 shares of the company’s stock valued at $6,292,000 after buying an additional 13,354 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Cable One by 11.0% during the first quarter. Vanguard Group Inc. now owns 490,178 shares of the company’s stock valued at $207,409,000 after acquiring an additional 48,513 shares in the last quarter. Private Management Group Inc. grew its holdings in shares of Cable One by 70.7% during the second quarter. Private Management Group Inc. now owns 113,641 shares of the company’s stock valued at $40,229,000 after buying an additional 47,082 shares during the last quarter. Public Sector Pension Investment Board purchased a new position in shares of Cable One in the second quarter worth about $3,554,000. Finally, Marshall Wace LLP purchased a new stake in shares of Cable One in the 2nd quarter valued at $1,410,000. 89.92% of the stock is owned by hedge funds and other institutional investors. Cable One Trading Up 3.4 % Shares of Cable One stock opened at $416.55 on Friday. The company has a current ratio of 0.93, a quick ratio of 0.93 and a debt-to-equity ratio of 1.84. Cable One, Inc. has a twelve month low of $311.28 and a twelve month high of $574.53. The firm has a market capitalization of $2.34 billion, a PE ratio of 9.63 and a beta of 0.84. The firm’s 50-day moving average price is $360.33 and its 200 day moving average price is $363.29. Cable One Announces Dividend Analyst Upgrades and Downgrades Separately, JPMorgan Chase & Co. lowered their price objective on Cable One from $480.00 to $470.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $531.67. Get Our Latest Research Report on Cable One About Cable One ( Free Report ) Cable One, Inc, together with its subsidiaries, provides data, video, and voice services in the United States. The company offers residential data services, a service to enhance Wi-Fi signal throughout the home. It also provides various residential video services from basic video service to digital services with access to hundreds of channels; and provides a cloud-based DVR feature that does not require the use of a set-top boxes. See Also Five stocks we like better than Cable One Manufacturing Stocks Investing Vertiv’s Cool Tech Makes Its Stock Red-Hot Quiet Period Expirations Explained MarketBeat Week in Review – 11/18 – 11/22 How to Use the MarketBeat Stock Screener 2 Finance Stocks With Competitive Advantages You Can’t Ignore Receive News & Ratings for Cable One Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cable One and related companies with MarketBeat.com's FREE daily email newsletter .
NoneSoftware firm Pony AI debuts on U.S. stock market
Though dyslexia is common, it's not always picked up and can be misunderstood. The learning difficulty can mean that your child is struggling with reading, writing and understanding overall. However, if picked up early your child can get the support they need. This is why it's vital to understand the signs which could help identify whether your child has dyslexia. Vasilii Kiselev, CEO and co-founder of Legacy Online School , an online education platform that provides high-quality online education has put together a list of signs to look out for so that your child gets the help they need. 1. Struggling with nursery rhymes If your child struggles to learn or remember nursery rhymes, it could be more than just a temporary issue. Difficulty with rhyming may indicate a challenge with sound recognition, a key reading skill that is often impacted by dyslexia. 2. Little interest in letters or words Children with dyslexia may love listening to stories but often show little interest in letters or words. "They’re drawn to the story itself but have difficulty connecting with written language," says Vasilii. "This can lead to early struggles with reading." 3. Alphabet aversion Learning to sing or recite the alphabet is a common early milestone, but for children with dyslexia, it can be a challenging task. If your child has noticeable difficulty remembering or singing their ABCs, it may be worth paying closer attention. 4. Speech mix-ups Mixing up parts of words, such as saying "cubumber" instead of "cucumber" or "flutterby" instead of "butterfly," can suggest difficulty in processing and recalling sounds. While these word mix-ups can be cute, they may also be early signs of a speech or language challenge. 5. Rhythm roadblocks Children with dyslexia often find it difficult to maintain a simple rhythm, like clapping to a beat. This struggle with rhythm can indicate challenges with sequencing and auditory processing, which are both associated with dyslexia. 6. Two-step tro uble If your child has difficulty following multi-step instructions, such as "put the toys in the box, then place the box on the shelf," they may feel overwhelmed by too much information at once. Frequently struggling with tasks that require following a sequence could be a sign of dyslexia. 7. Forgetfulness with familiar names Children with dyslexia often struggle to recall the names of familiar people, colours, or objects. "This forgetfulness isn’t due to a lack of attention, but rather because they have difficulty linking names with the concepts they represent," says Vasilii. 8. Directional confusion If your child often confuses words like "up" and "down" or other directional terms, it may be more than just typical early learning mix-ups. Difficulty distinguishing directions is common in dyslexia and can be an early indicator of spatial awareness challenges. 9. Family history of reading struggles A family history of dyslexia or reading difficulties can raise the likelihood that a child will face similar challenges. While it's not certain, genetics often contribute, making early observation even more important. 10. Good days and bad days Does it seem like your child has "good" and "bad" days without any clear reason? "Children with dyslexia may have fluctuating performance due to factors like fatigue or stress, which can affect their focus and behaviour," says Vasilii. Vasilii adds: “Identifying dyslexia early on allows parents and educators to introduce support strategies that target a child’s specific needs, rather than letting them struggle silently or lose confidence in themselves. When children feel understood and supported, they begin to realise that their difficulties with reading or writing are just one part of their learning profile, not a reflection of their intelligence. “Early intervention can help them develop the skills they need while preserving their natural curiosity and love for learning. Targeted support, such as phonics-based reading programs, multisensory learning methods, and assistive technology, can open up pathways to success that might otherwise feel blocked. "But perhaps most importantly, when we acknowledge and address dyslexia from the start, we’re sending a powerful message that every child learns differently - and that’s okay.”
NoneNASSAU, Bahamas -- Javon Small scored five of his 31 points in overtime and Tucker DeVries added key free throws late in regulation and finished with 16 points as West Virginia beat No. 3 Gonzaga 86-78 in the Battle 4 Atlantis on Wednesday. Small's layup with under 2 minutes left in OT gave West Virginia a 79-75 lead. After a Gonzaga miss, Sencire Harris hit two free throws to make it a six-point lead. With 27.1 seconds left, Harris made a steal and scored on a dunk for an eight-point lead, putting the game out of reach. Amani Hansberry scored a career-high 19 points and Toby Okani added 10 for West Virginia (3-2). Braden Huff scored 19 points and Khalif Battle 16 for Gonzaga (5-1). Gonzaga showed its depth, outscoring the West Virginia bench 30-2. West Virginia’s only loss was by 24 points at Pitt, but the rebuild under Darian DeVries is showing promise. Gonzaga turned it over at midcourt late in regulation when Tucker DeVries poked it away from Nolan Hickman and raced the other way before getting fouled. DeVries made two free throws with 5.9 seconds left to tie it at 71-all. Battle inbounded the ball and got it back, but lost control on a drive as time expired. The shorter Mountaineers outrebounded Gonzaga 42-36 and shot 50% in the second half, battling the Zags to a draw in the paint. Nembhard had 12 assists and just one turnover in 43 minutes, but was 1 of 10 from the field. West Virginia will play Louisville on Thursday in the winner's bracket. Gonzaga faces No. 14 Indiana on the consolation side. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college basketball: https://apnews.com/hub/ap-top-25-college-basketball-poll and https://apnews.com/hub/college-basketball